...
首页> 外文期刊>Carcinogenesis >A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis
【24h】

A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis

机译:胶质瘤和小胶质细胞之间的对话,通过CCL2 / CCR2 / interleukin-6轴促进肿瘤侵袭

获取原文
获取原文并翻译 | 示例
           

摘要

Glioma cells in situ are surrounded by microglia, suggesting the potential of glioma-microglia interactions to produce various outcomes. As chemokines are important mediators of cell-cell communication, we sought first to identify commonly expressed chemokines in 16 human glioma lines. We found CCL2 (macrophage chemoattractant protein-1) messenger RNA to be expressed by the majority of glioma lines. However, these lines did not express the CCL2 receptor, CCR2, which was found on microglia. Next, we overexpressed CCL2 in the U87 glioma line, which has low basal level of CCL2, to investigate the hypothesis that glioma-secreted CCL2 interacts with microglia to affect glioma growth. Stable clones with 10- to 12-fold elevation of CCL2 have similar growth rate and invasive capacity as vector controls when cultured in isolation. However, in coculture with microglia in a three-dimensional collagen gel matrix, the invasiveness of CCL2-overexpressing clones was increased. Gene array analyses were then undertaken and they revealed that interleukin (IL)-6 was consistently increased in the coculture. Recombinant IL-6 enhanced the invasiveness of glioma cells when these were cultured alone, whereas a neutralizing antibody to IL-6 attenuated the microglia-stimulated glioma invasiveness. Finally, we found that human glioma specimens in situ contained IL-6 immunoreactivity that was expressed on CD68+ cells. This study has uncovered a mechanism by which glioma cells exploit microglia for increased invasiveness. Specifically, glioma-derived CCL2 acts upon CCR2-bearing microglia, which then produces IL-6 to stimulate gliomas. The CCL2/CCR2/IL-6 loop is a potential therapeutic target for the currently incurable malignant gliomas.
机译:原位的神经胶质瘤细胞被小胶质细胞包围,表明神经胶质瘤-小胶质细胞相互作用产生各种结果的潜力。由于趋化因子是细胞间通讯的重要介体,因此我们首先寻求鉴定16种人类神经胶质瘤细胞系中普遍表达的趋化因子。我们发现CCL2(巨噬细胞趋化蛋白-1)信使RNA的大多数神经胶质瘤系表达。但是,这些细胞系不表达在小胶质细胞上发现的CCL2受体CCR2。接下来,我们在基础水平较低的U87神经胶质瘤系中过表达CCL2,以研究神经胶质瘤分泌的CCL2与小胶质细胞相互作用影响神经胶质瘤生长的假说。分离培养时,CCL2升高10到12倍的稳定克隆具有与载体对照相似的生长速率和侵袭能力。然而,在三维胶原蛋白凝胶基质中与小胶质细胞共培养时,CCL2过表达克隆的侵袭性增加。然后进行基因阵列分析,他们发现白细胞介素(IL)-6在共培养中持续增加。单独培养时,重组IL-6增强了神经胶质瘤细胞的侵袭性,而针对IL-6的中和抗体减弱了小胶质细胞刺激的神经胶质瘤侵袭性。最后,我们发现原位人类神经胶质瘤标本含有在CD68 +细胞上表达的IL-6免疫反应性。这项研究发现了胶质瘤细胞利用小胶质细胞增加侵袭性的机制。具体而言,源自神经胶质瘤的CCL2作用于带有CCR2的小胶质细胞,然后产生IL-6刺激神经胶质瘤。 CCL2 / CCR2 / IL-6环是目前无法治愈的恶性神经胶质瘤的潜在治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号